Vericel scores FDA approval for $142M burn treatment


Three and a half years after licensing it from an Israeli pharma in a $142 million deal, Vericel Corporation has won FDA approval for NexoBrid, a gel designed to treat serious burns.

Previous Louisville Business First's most read stories of 2022
Next Denver locking pill bottle manufacturer aims to get device covered by health insurers